This article was originally published on 11 November 2013 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. The JCVI subsequently reversed this position in March 2014, recommending Bexsero for routine infant immunisation.
The JCVI interim statement
In June 2013 the UK Joint Committee on Vaccination and Immunisation (JCVI) concluded that Bexsero® (4CMenB, Novartis Vaccines) was unlikely to be cost-effective for infant and toddler immunisation "at any vaccine price based on the accepted threshold for cost effectiveness used in the UK." The decision was a significant setback for Novartis, which had invested 17 years and considerable resource into developing the first broadly effective meningococcal B vaccine, and caused great disappointment among the meningitis research and patient community.
Scientific inputs to the model
The cost-effectiveness model developed by the University of Bristol and London School of Hygiene and Tropical Medicine centres on three key scientific inputs: disease burden, vaccine strain coverage, and vaccine impact on carriage. A critical factor is that meningococcal B disease burden in the UK has fallen significantly since the late 1990s - from 1,400 cases in 1998/99 to 614 cases in 2011/12 - reducing the denominator on which cost-effectiveness is calculated.
Novartis' Meningococcal Antigen Typing System (MATS) predicts vaccine effectiveness against 73-88% of UK MenB strains, and the company hoped new data suggesting MATS underestimates coverage would influence the reassessment. Critically, however, a Phase 3 study in 2,968 university students found that while two doses of Bexsero® elicited strong immune responses, no clear association between carriage rates and antibody levels was identified - denying the vaccine the "herd effect" that MenC vaccination had demonstrated so powerfully.
Predicted Bexsero® coverage of UK meningococcal B strains using the MATS prediction system
"Retrospective analysis of the success of MenC vaccination has scientifically set the bar too high for the group B vaccine. The JCVI appears to want the same evidence for a different vaccine."
The economic case
The Meningitis Research Foundation (MRF) submitted a detailed response to the JCVI arguing that the current cost-effectiveness model is too simplistic - failing to quantify the impact on family members, carers and the healthcare system as a whole. A case of serogroup B disease can account for millions of pounds over an affected child's lifetime in severe cases, and NHS litigation costs have not been modelled. Whether other currently used vaccines (HPV, rotavirus) would have been approved under the same JCVI methodology is a pertinent question raised at the MRF meeting.